

MEDIA RELEASE

Thomson Medical Group Reports Revenue, EBITDA and Operating Profit Growth for Q1 2019

Singapore, 13 May 2019 – SGX Mainboard-listed Thomson Medical Group Limited (“**the Group**”) today announced its financial results (“**Q1 2019**”) for the first quarter ended 31 March 2019.

The Group reported revenue growth of 3.8% for its healthcare business from \$52.5 million in Q1 2018 to \$54.5 million in Q1 2019. Revenue rose on the back of higher inpatient volumes and higher average bill sizes at the Group’s hospitals and specialist clinics in Singapore and Malaysia. Adjusted EBITDA increased by 13.6% from \$11.8 million in Q1 2018 to \$13.4 million in Q1 2019.

Operating profits rose 16.0% from \$8.1 million in Q1 2018 to \$9.4 million in Q1 2019, showing the strength of the Group’s underlying core healthcare business. However, financing costs associated with the takeover of healthcare assets last year continue to drag down overall net profit. Q1 net profit for 2019 came in at \$2.0 million, down from \$4.3 million in Q1 2018.

Going forward, the Group will continue its strategy of extending its market leadership position in women and children’s health and fertility, while developing new core specialities in oncology and wellness and lifestyle services.

In Singapore, the Group expects to open its new flagship multi-specialty centre at Paragon Medical Centre in phases from late July 2019. The new centre will house an integrated facility offering fertility treatment, obstetrics & gynaecology services, TCM, sports medicine, preventive medicine and wellness services, aesthetics and diagnostic imaging services. The Group will also be embarking on the expansion of its Thomson Women’s Cancer Centre network in collaboration with Brigham Health International and Dana-Farber Cancer Institute. A new Thomson Breast Centre will also be set up in the upcoming quarter.

In Malaysia, expansion works at Thomson Hospital Kota Damansara are on track with the basement bunker and lower floors completed. Construction of the new wing with additional capacity for 400 beds is projected to be completed by end-2020. In Johor Bahru, piling works for the new Thomson Iskandar Medical Hub, which includes the 500-bed Iskandariah Hospital, is expected to be done by Q3 2019.



Construction Progress for Thomson Hospital Kota Damansara Expansion – May 2019



Piling works progress for Thomson Iskandar Medical Hub – May 2019

– End –

About Thomson Medical Group Limited (<https://www.thomsonmedicalgroup.com>)

Listed on the Mainboard of the Singapore Exchange, Thomson Medical Group Limited is one of Asia's largest healthcare players with operations in Singapore and Malaysia.

Established in 1979, the Group's Thomson Medical Pte Ltd is Singapore's largest private provider of healthcare services for women and children. It owns and operates the iconic Thomson Medical Centre and a network of specialist medical clinics and facilities in Singapore.

The Group's operations in Malaysia under TMC Life Sciences Berhad is a multi-disciplinary healthcare company listed on Bursa Malaysia. It operates Thomson Hospital Kota Damansara, a tertiary hospital located in Kota Damansara, and the award-winning TMC Fertility Centre which is the industry leader in assisted reproduction technologies in Malaysia. It also owns the Thomson Iskandar Medical Hub, in Johor Bahru, Malaysia.

For more information, please visit: www.thomsonmedicalgroup.com.

For media enquiries, kindly contact:

Warren Wu

Corporate Communications, Thomson Medical Group Limited

Tel: (+65) 6933 8263

Mobile: (+65) 9170 0175

Email: warrenwu@thomsonmedical.com